Alexander M. Menzies
Expertise in
4
conditions

Alexander M. Menzies

Mater And Royal North Shore Hospitals
Sydney, NSW, AU 
Expertise in
4
conditions
Mater And Royal North Shore Hospitals
Sydney, NSW, AU 

Overview

Alexander Menzies practices practicing medicine in Sydney, Australia.

Mr. Menzies is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Melanoma, Metastatic Brain Tumor, Lung Metastases, and Brain Tumor.

He is actively involved in clinical research, co-authoring 345 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Mater and Royal North Shore Hospitals
Sydney, NSW, Australia
Other Locations
40 Rocklands Rds, Wollstonecraft, NSW 2065, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C/D (Excluding In-transit) Melanoma
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C/D (Excluding In-transit) Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib, Pembrolizumab
Study Phase: Phase 2
A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma
A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma
Enrollment Status: Terminated
Publish Date: April 18, 2023
Intervention Type: Drug
Study Drugs: Tigilanol Tiglate, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

345 Total Publications

Analytical Performance of the Avida Duo Assay for Simultaneous Mutation and Methylation Profiling in Circulating Cell-Free DNA.
Analytical Performance of the Avida Duo Assay for Simultaneous Mutation and Methylation Profiling in Circulating Cell-Free DNA.
Journal: Cancers
Published: May 23, 2026

Frequently Asked Questions about Alexander M. Menzies

Is Alexander M. Menzies a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Alexander M. Menzies is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alexander M. Menzies participate in research or clinical trials?

Yes. Alexander M. Menzies has published 345 articles and abstracts on conditions like Melanoma. You can view a list of Alexander M. Menzies's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Menzies's expertise for a condition
ConditionClose
    View All 39 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile